NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) is scheduled to be announcing its earnings results after the market closes on Thursday, May 6th.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last released its quarterly earnings data on Wednesday, March 24th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $1.89 million for the quarter. NovaBay Pharmaceuticals had a negative net margin of 122.78% and a negative return on equity of 309.15%. On average, analysts expect NovaBay Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NYSEAMERICAN:NBY traded down $0.03 during trading hours on Tuesday, reaching $0.77. The company’s stock had a trading volume of 7,238 shares, compared to its average volume of 4,267,706. The firm has a 50 day simple moving average of $0.66. The stock has a market cap of $32.09 million, a P/E ratio of -1.91 and a beta of 3.50. NovaBay Pharmaceuticals has a 12 month low of $0.52 and a 12 month high of $1.94.

Separately, Zacks Investment Research lowered NovaBay Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 31st.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products to address therapeutic needs of the anti-infective market in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx for the aesthetic dermatology market; and NeutroPhase for the wound care market.

Read More: What is the definition of arbitrage?

Earnings History for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with's FREE daily email newsletter.